Unlocking Europe: Your Strategic Guide to CE Marking for Medical Devices Under the MDR, from Technical Dossiers to Notified Bodies, Presented by Pure Global
MP3•Episode home
Manage episode 502922068 series 3684506
Content provided by Ran Chen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ran Chen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of MedTech Global Insights, we demystify the complex process of obtaining a CE mark for medical devices under the European Union's stringent Medical Device Regulation (MDR). We move beyond the basics to explore the critical strategic pillars required for success, from accurate device classification and building a bulletproof Quality Management System to compiling a Technical Dossier that meets the rigorous new standards for clinical evidence. Discover why the MDR is more than just a regulatory update; it's a new paradigm for product lifecycle management. We break down the crucial role of Notified Bodies, the bottlenecks that can delay your market entry by years, and the often-underestimated requirements for post-market surveillance that are essential for maintaining your access to one of the world's largest MedTech markets. A real-world example: A promising MedTech company, fresh off FDA clearance, invests over a year preparing for their European launch. They submit their file, only to be rejected by their Notified Body due to 'insufficient clinical evidence.' The market opportunity is slipping away as they now face costly delays to generate new data. This episode provides the strategic foresight to prevent this from happening to you. 本期干货 * Why is the new EU MDR so much more demanding than the old directive? * What is the most critical mistake companies make when classifying their medical device for the EU? * How can you structure your Technical Dossier to avoid the most common rejection points from Notified Bodies? * Is your Quality Management System truly prepared for an unannounced audit? * What are the hidden post-market surveillance duties that could force you to withdraw your product? * How do you select the right Notified Body and ensure your submission gets prioritized? * What specific clinical evidence does the EU demand that often goes beyond FDA requirements? * How can you leverage a single regulatory process to access multiple international markets beyond the EU? Contact us at [email protected] or visit https://pureglobal.com/ for more information.
…
continue reading
17 episodes